Summary
Eli Lilly and Company (LLY) filed an 8-K on June 4, 2012, to report a significant change in its Board of Directors. The company elected Dr. William G. Kaelin, Jr., a highly respected oncologist and researcher, as a new board member. This appointment is effective immediately and is intended to fill a vacancy left by the retirement of Dr. Martin Feldstein. Dr. Kaelin's expertise is expected to be valuable to the company, particularly given his roles on the science and technology committee and the finance committee. He will serve on an interim basis until the company's annual meeting in May 2014, when he will stand for election by shareholders. Dr. Kaelin brings a wealth of experience from his academic and research positions, including professorships at Dana-Farber Cancer Institute and Brigham and Women's Hospital. His extensive background in cancer research and his numerous accolades, including prestigious awards and memberships in national academies, suggest a strong scientific acumen that could benefit Lilly's strategic direction and innovation efforts. The appointment signals a commitment to strengthening the board's scientific advisory capabilities.
Key Highlights
- 1Eli Lilly & Co. appointed Dr. William G. Kaelin, Jr. to its Board of Directors, effective June 4, 2012.
- 2Dr. Kaelin is a distinguished Professor of Medicine at Dana-Farber Cancer Institute and Brigham and Women's Hospital, bringing significant expertise in oncology.
- 3The new director will serve on the company's Science and Technology Committee and the Finance Committee.
- 4Dr. Kaelin's appointment fills a vacancy created by the retirement of Dr. Martin Feldstein.
- 5He will serve under an interim election and will be presented for shareholder election at the May 2014 annual meeting.
- 6Dr. Kaelin is a recognized leader in cancer research with numerous awards and memberships in prestigious scientific bodies like the National Academy of Sciences.